BEGIN:VCALENDAR PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN VERSION:2.0 BEGIN:VEVENT DESCRIPTION:Whilst PROTACs continue to make headwind\, much of the heterob ifunctional and monovalent opportunity beyond the ubiquitin proteosome sy stem remains untapped\, drawing in new and distinguished biopharma in the race to develop new stabilization\, modulation\, post-translational modi fication\, and inactivation/activation modalities. Taking on this emergin g proximity phenomenon is no easy feat as knowledge gaps persist in valid ating novel mechanisms of action\, accessing diverse chemical matter\, an d rationally designing selective and potent small molecules and biologics for novel target spaces.\n\nOwing to this\, the 4th Annual Induced Proxi mity-Based Drug Discovery Summit returns as the definitive and first esta blished forum dedicated to gaining proof of concept for protein stabiliza tion\, modulation and post-translational modification.\n\nAs the communit y makes early strides\, answer your burning questions with data-driven pr esentations\, technical discussions\, and interactive sessions as we unit e 100+ induced proximity experts devoted to exploring the application of induced proximity in diverse fields in and beyond protein degradation.\n\ nURLs:Tickets: \;https://go.evvnt.com/2313820-2?pid=185Brochure:  \;https://go.evvnt.com/2313820-3?pid=185\n\nPrices:Conference + 2 Worksho ps (Drug Developer Pricing): USD 4197.00\,Conference + 1 Workshop (Drug D eveloper Pricing): USD 3598.00\,Conference Only (Drug Developer Pricing): USD 2999.00\,Conference + 2 Workshops (Research Institute Pricing): USD 3597.00\,Conference + 1 Workshop (Research Institute Pricing): USD 3098.0 0\,Conference Only (Research Institute Pricing): USD 2599.00\,Conference + 2 Workshops (Service Provider Pricing): USD 5097.00\,Conference + 1 Wor kshop (Service Provider Pricing): USD 4398.00\,Conference Only (Service P rovider Pricing): USD 3699.00\n\nSpeakers: \;Andrew Zhang\, Director\ , Chemical Biology\, AstraZeneca\, Brandon Turunen\, Co-Founder and Chief Technology Officer\, Solu Therapeutics\, Changhoon Ji\, Executive Direct or\, AUTOTAC Bio\, Charles Y.\, Lin Senior Vice President - Research and Development\, Kronos Bio\, Christian Münch\, Professor and Director of Pr oteomics\, Goethe University Frankfurt\, Christopher Phelps\, Senior Vice President and Head of Early Drug Discovery\, Nurix Therapeutics\, Edmund Graziani\, Chief Executive Officer\, Apertor Pharmaceuticals\, Heidi Gre ulich\, Senior Group Leader\, The Broad Institute of MIT and Harvard\, Ju n Qi\, Assistant Professor – Medicine\, Dana-Farber Cancer Institute\, Ka thleen Seyb\, Senior Vice President - Biology and Translational Sciences\ , TRIANA Biomedicines\, Katie Spooner\, Research Analyst\, Beacon\, Kelly Rainbolt\, Senior Scientist - Biochemical and Cellular Engineering\, Lyt erian Therapeutics\, Lokesh Gakhar\, Senior Director and Head of Structur al Biology and Protein Sciences\, PAQ Therapeutics\, Matthew Hayward\, Vi ce President of Drug Discovery\, Magnet Biomedicine\, Moses Moustakim\, S enior Scientist - Chemistry\, Photys Therapeutics\, Rick Ewing\, Vice Pre sident and Head of Chemistry\, Rapafusyn Pharmaceuticals\, Shyra Gardai\, Chief Scientific Officer\, EpiBiologics\, Sriram Subramaniam\, Chief Exe cutive Officer and Founder\, Gandeeva Therapeutics\, Thomas Pillow\, Seni or Scientist\, Genentech\, Trevor Zandi\, Postdoctoral Scientist\, Novart is Biomedical Research\, Tyzoon Nomanbhoy\, Vice President\, Chemical Bio logy\, Vicinitas Therapeutics\n\nDate and Time: \;23rd July 2024 at 9 :00 am to 25th July 2024 at 5:00 pm\n DTEND:20240725T170000 DTSTAMP:20260512T232941Z DTSTART:20240723T090000 LOCATION:The Hyatt Regency\, 1 Ave de Lafayette\, Boston\, Massachusetts\, 02111\, SEQUENCE:0 SUMMARY:Whilst PROTACs continue to make headwind\, much of the heterobifun ctional and monovalent opportunity beyond the ubiquitin proteosome system remains... UID:656a7fc0-385b-4560-9abc-8c6c19ae7146 END:VEVENT END:VCALENDAR